Search clinical trials for: CRAD001

Total 6 results

Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
Novartis Pharmaceuticals

Completed

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Canada
Novartis Pharmaceuticals

Completed

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (EVEREXES)

Post Menopausal Breast Cancer

Taiwan, Malaysia, Turkey, Australia, Korea, Republic of, Thailand, Jordan, India, Vietnam, Morocco, Tunisia, Indonesia, South Africa
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients (CONCERVIC)

Hepatitis C | Renal Allograft

Brazil
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NECTAR)

Breast Cancer | Triple Negative Breast Cancer

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Completed

Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

Prostate Cancer

France

Search clinical trials for: CRAD001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations